Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

Phase 2

Terminated

• Conditions: Colorectal Neoplasms; Metastases, Neoplasm

• Registration Number: NCT00065117
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-07-17
• Study First Submitted QC: 2003-07-17
• Study First Posted: 2003-07-18
• Study Start: 2003-09
• Primary Completion: 2004-02
• Study Completion: 2004-02
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-25
• Last Update Posted: 2011-01-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Metastatic colorectal carcinoma
• Suitable for first-line treatment of metastatic disease

Exclusion Criteria

• Peripheral neuropathy greater than Grade 1
• Adjuvant therapy within 6 months prior to study treatment
• Prior oxaliplatin
• Prior pelvic or whole abdomen radiation
• Any history of coronary angioplasty or history of myocardial infarction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Research Site; 🇺🇸 Pittsburgh, Pennsylvania, United States